Obviously, further investigations are required to establish the validity of this approach, but investigation of the KRAS and PIK3CA mutation status of non-diseased uterine tissue of adenomyosis patients might greatly aid in surgical decision-making and therapeutic management. The gene discussed is PIK3CA; the disease is adenomyosis.